Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95700 | 0.77 | CA1 (0.39) | MAPTHTTGAAKLK7KMT2A | |
| SCHEMBL12569502 | 0.74 | ALDH1A1 (0.62) | ALDH1A1MAPTKDM4EHTTMAPK1 | |
| SCHEMBL12136707 | 0.72 | MAPT (0.47) | ALDH1A1MAPTKDM4EHTTMAPK1 | |
| SCHEMBL13125298 | 0.72 | ALDH1A1 (0.57) | ALDH1A1MAPTKDM4EHTTMAPK1 | |
| SCHEMBL12050118 | 0.71 | MMP1 (0.33) | — | |
| SCHEMBL1085724 | 0.71 | ALDH1A1 (0.58) | ALDH1A1MAPTKDM4EHTTMAPK1 | |
| SCHEMBL13660164 | 0.70 | ALDH1A1 (0.46) | ALDH1A1MAPTKDM4EHTTMAPK1 | |
| SCHEMBL12136699 | 0.70 | MAPT (0.52) | ALDH1A1MAPTKDM4EHTTMAPK1 | |
| SCHEMBL12136703 | 0.70 | MAPT (0.52) | ALDH1A1MAPTKDM4EHTTMAPK1 | |
| SCHEMBL12658257 | 0.70 | MAPT (0.49) | ALDH1A1MAPTKDM4EHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362270-B2 | Self-assembled nanostructures | XEROX CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362270-B2 | Self-assembled nanostructures | XEROX CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110282072-A1 | SELF-ASSEMBLED NANOSTRUCTURES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2011-11-17 | — | — | US | disclosed |
| US-20110282072-A1 | SELF-ASSEMBLED NANOSTRUCTURES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2011-11-17 | — | — | US | disclosed |
| EP-2322512-A1 | Alkylated benzimidazolone compounds and self-assembled nanostructures generated therefrom | Xerox Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282072-A1 | SELF-ASSEMBLED NANOSTRUCTURES | RB1, CNKSR1, RBBP4 | ALDH1A1 920/4885MAPT 3230/4885KDM4E 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.